Genmab A/S ADS (GMAB)
NASDAQ: GMABHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GMAB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $31.20B
- P/E (TTM)
- 43.25
- Forward P/E
- 32.03
- EPS (TTM)
- $1.17
- Dividend yield
- None
- 52-week range
- 23.62 – 59.97
- Day range
- 50.24 – 51.72
- Volume / Avg
- 2.90M / 4.18M
- Beta
- —
- Shares outstanding
- 616.59M
52-week range
GMAB stock today
Genmab A/S (GMAB) closed at $50.60 on Nov 20, down 1.46% (-$0.75), versus the S&P 500's 3.70% decline. Shares are 15.6% below their 52-week high of $59.97, set on Oct 28, 2026 and 114.2% above the 52-week low of $23.62, in the middle of the past year's range. GMAB is up 64.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 66.2%.
At 43.2x trailing earnings, Genmab A/S trades above the peer-group median of 20.9x. Its forward P/E of 32.0x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Genmab A/S
Company profileGenmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Jan G.J. van de Winkel Ph.D.
- Headquarters
- Copenhagen
- Employees
- 3,244
- IPO year
- 2019
- Website
- genmab.com
Financial highlights
Full financialsIn fiscal 2025, Genmab A/S generated $3.72 billion in revenue, up 19.2% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $963.0 million (-15.0% year over year), for a net margin of 25.9% versus a median of 31.4% in the prior 2 years. Gross margin was 93.6% (down from 95.4%) and operating margin 28.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $3.72B | $3.12B | $2.39B |
| Growth | +19.19% | +30.59% | — |
| Net income | $963.00M | $1.13B | $631.00M |
| EPS (diluted) | $15.37 | $17.53 | $9.58 |
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$65.01+28.48%
- Strong buy 1
- Buy 9
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $0.56 vs $0.36
- Surprise
- +55.56%
GMAB news
All GMAB news- Grant of Restricted Stock Units and Warrants to Employees in GenmabGlobeNewswire
- Genmab A/S Discloses Share Transactions on November 10, 2026Nasdaq
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsGlobeNewswire
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsGlobeNewswire
- Genmab A/S (GMAB) Presents at 8th Annual Wolfe Research Healthcare Conference TranscriptSeeking Alpha
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsGlobeNewswire
- Capital Increase in Genmab as a Result of Employee Warrant ExerciseGlobeNewswire
- Genmab (GMAB) Q3 2026 Earnings Call TranscriptNasdaq
Genmab A/S peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| INSMInsmed Incorporated | 141.33 | -2.17% | $31.01B | vs GMAB |
| ZTSZoetis Inc. Class A | 79.11 | -2.08% | $32.14B | vs GMAB |
| ROIVRoivant Sciences Ltd. | 38.66 | -0.78% | $28.01B | vs GMAB |
| UTHRUnited Therapeutics Corporation | 554.73 | -0.78% | $23.63B | vs GMAB |
| RPRXRoyalty Pharma plc Class A | 68.45 | +1.08% | $39.36B | vs GMAB |
| VTRSViatris Inc. | 19.63 | -1.26% | $22.50B | vs GMAB |
| ALNYAlnylam Pharmaceuticals Inc. | 143.82 | -2.71% | $19.26B | vs GMAB |
| ONCBeOne Medicines Ltd. ADR | 390.94 | -2.19% | $44.66B | vs GMAB |
Indexes, lists and sector
Genmab A/S stock FAQ
What is Genmab A/S's stock price today?
GMAB last traded at $50.60 as of Nov 20, 4:00 PM EST, down 1.46% on the day. Prices are delayed at least 15 minutes.
Does Genmab A/S pay a dividend?
No. Genmab A/S does not currently pay a regular cash dividend.
What is GMAB's P/E ratio?
GMAB trades at a trailing P/E ratio of 43.25 and a forward P/E of 32.03, compared with a median of 20.9 for its closest peers.
Who is Genmab A/S's CEO?
Dr. Jan G.J. van de Winkel Ph.D. is the chief executive officer of Genmab A/S ADS, which has about 3,244 employees.
Has GMAB ever split its stock?
Yes. The most recent GMAB stock split was a 5-for-1 split on May 1, 2018.
What is the GMAB 52-week high?
The 52-week high for GMAB is $59.97 and the 52-week low is $23.62. The stock is currently 15.6% below its high.